Search

everythinglearnresearchcommunity

for

Search:↓

Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.

IL-1 receptor absence in mice leads to skin cysts and changes in immune response after UVB exposure.

Chronic inflammatory skin diseases are caused by disrupted interactions between skin cells and immune cells.

MicroRNAs are crucial in controlling cell signaling, affecting cancer and tissue regeneration.

Early regulatory T cells are crucial for normal skin pigmentation.

Cells from the lower part of hair follicles are a promising, less invasive option for immune system therapies.

IL-9/IL-9R signaling can negatively affect human hair growth and may be a target for treating hair loss conditions.

Belatacept may be a promising treatment for alopecia areata.

Deleting Snai2 and Snai3 causes fatal autoimmunity.

Certain cytokines may cause or be affected by immune skin diseases, suggesting possible new treatments.

Contact immunotherapy might help treat various skin conditions, but more research is needed to confirm its safety and effectiveness.

Chronic refractory alopecia areata has more skin-resident memory T cells, and JAK inhibitors may help reduce them.

The skin can independently form immune responses through special structures, offering new ways to treat skin diseases.

Basal cell carcinomas may use IDO to protect themselves from the immune system.

Alopecia areata is linked to immune system differences, with specific biomarkers like CXCL9 and CXCL10 being key for diagnosis and potential treatment targets.

Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.

In alopecia areata, certain immune cells increase and express a protein linked to immune activation.

Alopecia areata and atopic dermatitis share immune system issues, and treatments like JAK inhibitors can help both.

Higher PD-1 levels are linked to fewer immune cells in hair follicles in alopecia areata.

Inhibiting TYK2 can restore hair growth in alopecia areata.

Targeting SIRT1 with antisense oligonucleotides could be a promising treatment for hair loss.

Injecting recipient splenocytes into donors' thymus can prevent graft-versus-host disease.

Targeting amphiregulin may improve treatment for fibrosis and cancer.

The study suggested certain immune cells might cause alopecia areata, but it was retracted.

CGRP may help protect hair follicles from immune system attacks, potentially slowing hair loss.

Immune cells might contribute to hair loss caused by a specific mutation.

Tacrolimus causes fewer acute rejections than cyclosporin A in kidney transplants but doesn't necessarily improve kidney function after one year; cardiovascular risks and side effects vary between the two drugs.

HDAC4 and HDAC7 are crucial for Th17 cell development and could be targeted to treat inflammatory diseases.

Skin problems from transplant drugs are common and need careful management in organ transplant patients.